SyncThink has gained FDA approval for Eye-Sync, its eye-tracking device that scans abnormal eye movement and diagnoses concussion in less than 60 seconds
Created in collaboration with the Brain Trauma Foundation, SyncThink developed Eye-Sync as an eye tracking assessment that measures accurate tracking of predictable visual target motion.
Eye-Sync is an integrated, head-mounted, eye-tracking device for rapid recording, viewing and analysing of eye movement impairment through the use of virtual reality.
Abnormal eye movement is one of the most common deficits after a concussion occurs. Eye-Sync uses eye-tracking technology to monitor eye movement in a handheld virtual reality environment.
Jamshid Ghajar, chairman of the board, chief scientific adviser and founder of SyncThink, said: "I use the Eye-Sync device on all my patients in the Stanford Concussion and Brain Performance centre. It gives me a rapid and accurate metric to diagnose concussion and recovery."
SyncThink currently has ten granted patents and a normative database that includes more than 10,000 individuals, as well as more than 40 peer-reviewed research articles characterising the impact of concussion on visual attention.
"In my opinion, the Eye-Sync device has significant implications for sideline evaluation [in sports], and I can see in the future how this can be the diagnostic gold standard for sports related concussion,” said Scott Anderson, director of athletic training for Stanford University Sports Medicine.